Announcements
- argenx Reports First Quarter 2024 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2024 Health Care Conference
- argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
- argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
- argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
- argenx Announces Annual General Meeting of Shareholders on May 7, 2024
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
- argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
- argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- argenx to Present at Upcoming Investor Conferences
More ▼
Key statistics
As of last trade argenx SE (ARGXN:MEX) traded at 6,385.68, 0.00% above its 52-week low of 6,385.68, set on Apr 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6,385.68 |
---|---|
High | 6,385.68 |
Low | 6,385.68 |
Bid | 6,500.00 |
Offer | 6,385.68 |
Previous close | 6,385.68 |
Average volume | -- |
---|---|
Shares outstanding | 59.43m |
Free float | 59.35m |
P/E (TTM) | -- |
Market cap | 21.90bn USD |
EPS (TTM) | -5.66 USD |
Data delayed at least 20 minutes, as of Apr 24 2024 12:30 BST.
More ▼